Oncolytic potential of Newcastle Disease Virus in feline lymphoma cells: an in vitro evaluation.

NDV-GFP demonstrates oncolytic activity against feline lymphoma cells in vitro.

Feline lymphoma represents a significant clinical challenge in veterinary oncology, with many patients developing treatment resistance or relapse following conventional chemotherapy. This in vitro study investigates Newcastle Disease Virus expressing green fluorescent protein (NDV-GFP) as a potential oncolytic therapy for feline lymphoma. Newcastle Disease Virus is an avian paramyxovirus with established safety profiles in less virulent vaccine strains. The researchers evaluated NDV-GFP's ability to infect, replicate in, and induce apoptosis in feline lymphoma cells derived from a FeLV-positive patient with thymic lymphoma. Results demonstrated successful viral infection, replication, and apoptosis induction in the lymphoma cells, providing preliminary evidence for NDV's oncolytic activity in FeLV-induced lymphoma. This approach represents an emerging immunotherapeutic strategy that combines direct tumor cell elimination with immune system activation, addressing an important clinical need for alternative treatment options in feline patients with poor chemotherapy responses.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.